Fig 1.

Impact of the prodrug of gemcitabine LY2334737 (LY) or Gemcitabine HCl administration on mouse weights as well as CEP and White Blood Cell (WBC) counts in female Balb/c mice. Gemcitabine (Gem) was given i.p. (at doses of 40, 70, 120 or 160mg/kg) every three days (starting on day 1, then on days 4, 7 etc) up to day 25 when the last dose was administered. LY was given daily by gavage (at doses of 2, 4 and 6mg/Kg), and for all groups mice were bled on day 28. a) Chemical structure of LY2334737, Gemcitabine, and cyclophosphamide, b) No significant weight loss was observed in all groups throughout the treatment period. c) Viable CEP (top) and WBC (bottom) count for mice treated with the indicated doses of LY or Gemcitabine (Gem), showing no significant impact of LY on CEP numbers (no statistically significant difference between the groups), in the absence of overt toxicity as determined by relative WBC (no statistically significant difference was found between WBC for controls and for LY treated groups; the 40mg/kg Gem i.p treated group was significantly lower than controls, p<0.01).